Michelle Gilson serves as the Chief Financial Officer (CFO) at ARCELLX INC, a biotechnology company focused on developing innovative therapies for cancer and other diseases. In her role as CFO, Gilson is responsible for overseeing the financial operations of the company, including financial planning and analysis, accounting, and investor relations. Her strategic vision and financial acumen have been instrumental in guiding ARCELLX through its growth and development phases, ensuring the company's financial health and stability as it advances its mission to bring life-changing treatments to patients. Prior to joining ARCELLX, Gilson held several high-level financial positions at various organizations in the biotechnology and pharmaceutical sectors. She has a proven track record of successfully managing complex financial operations and driving growth in dynamic, fast-paced environments. Gilson's extensive experience in the industry, coupled with her strong leadership skills, have enabled her to make significant contributions to ARCELLX's success. Under her guidance, the company has been able to secure funding, forge strategic partnerships, and navigate the challenges of bringing new therapies to market. Gilson's achievements at ARCELLX include playing a key role in the company's successful initial public offering (IPO) and helping to establish a solid financial foundation for future growth. Her ability to communicate effectively with investors and stakeholders has been crucial in building confidence in ARCELLX's vision and strategy. As CFO, Gilson continues to be a driving force behind the company's financial strategy, working closely with the executive team to ensure that ARCELLX remains at the forefront of innovation in the biotechnology industry.